Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: A single institution experience

References

• Fraser C J, Hirsh B A, Dayton V, Creer M H, Neglia J P, Wagner J E, Kaber A S. First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood 2005; 106: 4377–4380
   PubMed Web of Science ®Google Scholar
• Spineli O, Giussani U, Borleri G, Lazzari M, Michelato A, Dotti G, et al. Need for an accurate molecular disgnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. Haematologica 2000; 85: 1153–1157
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, McArthur J. Leucemias agudas. Fundamentos de Hematología, 3rd edn, G J Ruiz-Argüelles. Editorial Médica Panamericana, México 2003; 225–245
   Google Scholar
• Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756–763
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M, van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs.-leukemia without myeoablative therapy. Blood 1997; 89: 4531–4536
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú O G, Jaime-Pérez J C. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241–244
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez O G, Jaime-Pérez J C, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894–896
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre C H, Vela-Ojeda J, García-Ruiz-Esparza M A, et al. for the Latin American Cooperative Oncohematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1(+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047
   PubMed Web of Science ®Google Scholar
• Martino R, Giralt S, Caballero M D, Mackinnon S, Corradini P, Fernández-Avilés F, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity coinditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003; 88: 555–560
   PubMed Web of Science ®Google Scholar
• Carella A M, Beltrami G, Carella M, Jr, Corsetti M T, Scalzulli R P, Greco M. Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease. Haematologica 2001; 86: 1121–1123
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002; 76(Suppl 1)376–379
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J. The Mexican approach to conduct allogeneic stem cell transplantation: braking dogmata and facing the Matthew effect. Hematology 2005; 10(Suppl 1)154–160
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, López-Martínez B, Santellán-Olea M R, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single instituition. Leuk Lymphoma 2002; 43: 1509–1511
   PubMed Web of Science ®Google Scholar
• Herzenberg L A, Parks D, Sahaf B, Perez O, Roederer M, Herzenberg L A. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem 2002; 48: 1819–1827
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K, et al. Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol 2005; 79: 294–298
   PubMed Web of Science ®Google Scholar
• Cooley L D, Sears D A, Udden M M. Donor cell leukemia: Report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000; 63: 46–53
   PubMed Web of Science ®Google Scholar
• Niederweiser D W, Appelbaum F R, Gastl G. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 1990; 322: 1794–1796
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Almaguer D, Gómez Rangel J D, Vela-Ojeda J, Cantú-Rodríguez O G, Jaime-Pérez J C, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma 2004; 45: 1191–1195
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, Gómez-Rangel J D, García-Ruiz-Esparza M A, et al. Extramedullary leukemic relapses following hematopoietic stem cell transplantation with non-myeloablative conditioning. Int J Hematol 2005; 82: 262–265
   PubMed Web of Science ®Google Scholar